GlpBio

Antibody-drug Conjugate (ADC)

Antibody-drug Conjugate (ADC)(抗体-药物偶联物 (ADC))

The antibody-drug conjugate (ADC), a humanized or human monoclonal antibody conjugated with highly cytotoxic small molecules (payloads) through chemical linkers, is a novel therapeutic format and has great potential to make a paradigm shift in cancer chemotherapy. This antibody-based molecular platform enables selective delivery of a potent cytotoxic payload to target cancer cells, resulting in improved efficacy, reduced systemic toxicity, and preferable pharmacokinetics (PK)/pharmacodynamics (PD) and biodistribution compared to traditional chemotherapy.

All three component parts of an ADC, the antibody, the cytotoxic agent, and the linker that joins them, are critical elements in its design. The antibody moiety should be specific for a cell surface target molecule that is selectively expressed on cancer cells, or overexpressed on cancer cells relative to normal cells. The payload of an ADC must be highly cytotoxic so that it can kill tumor cells at the intracellular concentrations achievable following distribution of the ADC into solid tumor tissue, and because only a limited number of payloads can be linked to an antibody molecule (typically an average of 3-4 payloads per antibody) without severely compromising its biophysical and pharmacokinetic properties. The cytotoxic compounds include derivatives of calicheamicin, a class of highly cytotoxic enediyne antibiotics which kill cells by causing DNA double-strand breaks, and derivatives of the potent antimitotic microtubule-disrupting agents, dolastatin 10 (auristatins) and maytansine.

The third vital component of an ADC is the linker that forms a chemical connection between the payload and the antibody. The linker should be sufficiently stable in circulation to allow the payload to remain attached to the antibody while in circulation as it distributes into tissues (including solid tumor tissue), yet should allow efficient release of an active cell-killing agent once the ADC is taken up into the cancer cells. Linkers can be characterized as either cleavable, or as non-cleavable.

Antibody-drug Conjugate (ADC) 相关产品(26)

  • GC61473 structure
    GC61473Trastuzumab deruxtecan
    CAS: 1826843-81-5
    纯度: >98.50% / >99.00%

    Trastuzumab deruxtecan（曲妥珠单抗）是一种人表皮生长因子受体2（HER2）靶向抗体-药物偶联物（ADC），由人源化抗人HER2（抗hHER2）抗体、酶促裂解肽接头和拓扑异构酶I抑制剂（DX-8951衍生物）组成。

  • GC61490 structure
    GC61490Trastuzumab emtansine
    CAS: 1018448-65-1
    纯度: >98.00%

    Trastuzumab Emtansine(T-DM1,Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1.Trastuzumab emtansine has a molecular weight of 145kDa.

  • GC64039 structure
    GC64039Disitamab vedotin
    CAS: 2136633-23-1
    纯度: >98.00% / >97.00%

    Disitamab vedotin是一种靶向HER2蛋白的抗体药物偶联物，由hertuzumab通过可裂解连接子与monomethyl auristatin E (MMAE)偶联而成。

  • GC64930 structure
    GC64930Sacituzumab govitecan
    CAS: 1491917-83-9

    Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) targeting Trop-2 for delivery of SN-38, showing anticancer activity. Sacituzumab govitecan has a molecular weight of 160KDa.Can be dissolved and diluted with PBS.

  • GC65286 structure
    GC65286INX-SM-6
    CAS: 2734878-16-9
    纯度: >98.00%

    INX-SM-6 可用于抗炎药的靶向输送。INX-SM-6 在 PBMCS 细胞中抑制 LPS 诱导的 IL-1β 的产生。

  • GC65287 structure
    GC65287INX-SM-56
    CAS: 2734878-18-1

    INX-SM-56 是一种抗 VISTA 抗体药物偶联物（anti-VISTA antibody drug conjugate），可用于抗炎药的靶向输送。VISTA:含 V 区免疫球蛋白的 T 细胞活化抑制因子。

  • GC68296 structure
    GC68296Brentuximab vedotin
    CAS: 914088-09-8
    纯度: >98.00% / >99.50%

    Brentuximab vedotin (cAC10-vcMMAE) 是一种抗体-药物偶联物 (ADC)，由抗 CD30 抗体和 Monomethyl auristatin E (MMAE) 组成。Brentuximab vedotin 抑制 CD30 阳性细胞，其 IC50 值为 2.5 ng/mL。Brentuximab vedotin 可用于复发难治性霍奇金淋巴瘤的研究。

  • GC69393 structure
    GC69393Loncastuximab tesirine
    CAS: 1879918-31-6
    纯度: >99.00%

    Loncastuximab tesirine 是一种人簇分化 19 (CD19) 靶向的抗体-活性分子偶联物 (ADC)。一旦与细胞膜上的 CD19 结合，Loncastuximab tesirine 被迅速内化，引发细胞死亡。Loncastuximab tesirin 诱导细胞凋亡，可用于弥漫型 B 细胞淋巴瘤的研究。

  • GC70007 structure
    GC70007Telisotuzumab vedotin
    CAS: 1714088-51-3
    纯度: >98.00%

    Telisotuzumab vedotin (ABBV-399) 是一种靶向 c-Met 的抗体-药物偶联物 (ADCs)。Telisotuzumab vedotin 由 Monomethyl Auristatin E (MMAE)、Telisotuzumab 抗体和可裂解的 mc-val-cit-PABC 型 linker 偶联而成。 Telisotuzumab vedotin 可用于癌症的研究。

  • GC73017 structure
    GC73017Polatuzumab vedotin
    CAS: 1313206-42-6
    纯度: >98.00%

    Polatuzumab vedotin是一种靶向CD79b的抗体-药物偶联物。

  • GC73018 structure
    GC73018Mirvetuximab soravtansine (solution)
    CAS: 1453084-37-1
    纯度: >99.00%

    Mirvetuximab soravtansine (solution)是一种抗叶酸受体α（FRα）ADC，由细胞毒性美登素类DM4组成，与人源化单克隆抗体M9346A共价连接。

  • GC73019 structure
    GC73019Depatuxizumab mafodotin
    CAS: 1585973-65-4
    纯度: >99.00%

    Depatuxizumab mafodotin是一种特异性靶向表皮生长因子受体（EGFR）的抗体-药物偶联物（ADC）。

  • GC73079 structure
    GC73079Datopotamab deruxtecan
    CAS: 2238831-60-0
    纯度: >98.00%

    Datopotamab deruxtecan (ds - 1062;Dato-DXd是一种滋养细胞表面抗原2 （TROP2）导向的抗体-药物偶联物（ADC）。

  • GC73080 structure
    GC73080Glembatumumab vedotin
    CAS: 1182215-65-1
    纯度: >99.00%

    Glembatumumab vedotin（CDX-011）是一种ADC，其包含针对糖蛋白NMB的全人IgG2单克隆抗体（CR011），并通过蛋白酶敏感的vc接头与细胞毒性剂MMAE偶联。

  • GC73408 structure
    GC73408Tisotumab vedotin
    CAS: 1418731-10-8
    纯度: >99.00%

    Tisotumab vedotin是一种靶向组织因子（TF）的ADC，通过将针对TF的全人单克隆抗体（TF-011）与微管破坏剂MMAE共价连接而形成。

  • GC73689 structure
    GC73689Depatuxizumab MMAE
    纯度: >99.00%

    Depatuxizumab MMAE是一种抗体-药物偶联物（ADC），由抗EGFR单克隆抗体（Depatuxizumab）和细胞毒性药物Monometl auristatin E （MMAE）组成。

  • GC74068 structure
    GC74068ORM-5029
    纯度: >99.00%

    ORM-5029是一种一流的人表皮生长因子受体2（HER2）靶向抗体药物偶联物（ADC），由SMol006组成，SMol006是一种高效的GSPT1降解剂，与Pertuzumab偶联。

  • GC74451 structure
    GC74451Enfortumab vedotin-ejfv (solution)
    CAS: 1346452-25-2
    纯度: >99.00%

    Enfortumab vedotin-ejfv (solution)是一种用于治疗尿路上皮癌的抗Nectin-4抗体药物偶联物。

  • GC74509 structure
    GC74509Azintuxizumab vedotin
    CAS: 1826819-58-2
    纯度: >98.00%

    Azintuxizumab vedotin（ABBV-838）是一种抗体-药物偶联物（ADC），靶向CD2亚群1的独特表位，CD2亚集1是一种在多发性骨髓瘤细胞上表达的细胞表面糖蛋白。

  • GC74519 structure
    GC74519Cantuzumab ravtansine
    CAS: 868747-45-9
    纯度: >98.00%

    Cantuzumab ravtansine（IMGN242；huC242-DM4）是一种ADC，是一种人源化单克隆抗体huC242，通过二硫键共价连接到DM4（DM4）。

  • GC74533 structure
    GC74533Tusamitamab ravtansine
    CAS: 2254086-60-5
    纯度: >99.00%

    Tusamitamab ravtansine（SAR-408701）是一种针对表达CEACAM5的肿瘤细胞的靶向ADC，由人源化抗CEACAM5单克隆抗体组成，该抗体通过可切割的接头与强效细胞毒性剂美登素类DM4共价连接。

  • GC74540 structure
    GC74540Sofituzumab vedotin
    CAS: 1418200-58-4
    纯度: >98.00%

    Sofituzumab vedotin (DMUC5754A)是一种含有mmae的抗muc16抗体-药物偶联物（ADC），具有蛋白酶可切割的连接物。

  • GC74544 structure
    GC74544Farletuzumab ecteribulin
    CAS: 2407465-18-1
    纯度: >98.00%

    Farletuzumab ecteribulin（MORAb-202）是一种ADC，由人源化抗人FRA抗体Farletuzumab通过减少的链间二硫键与Mal-PEG2-Val-Cit-PAB-eribulin结合而成。

  • GC74567 structure
    GC74567Labetuzumab govitecan
    CAS: 1469876-18-3
    纯度: >98.00%

    Labetuzumab govitecan（IMMU 130）是一种抗EACAM5/SN-38抗体药物偶联物（ADC）。